癌症研究
嵌合抗原受体
T细胞受体
生物
遗传增强
免疫疗法
T细胞
基因
医学
作者
Elaine S Tan,Neel Gakhar,Kedar Kirtane
标识
DOI:10.1016/j.beha.2021.101285
摘要
The engineering of immune cells to target cancer cells (cellular immunotherapy) has been an exciting area of development in recent years. One type of cellular therapy, T cell receptor (TCR) gene engineered therapy, has shown particular promise in solid tumors. Through use of a heterodimer to recognize intracellular tumor antigens presented through the major histocompatibility complex (MHC), TCR T cells are able to evoke a cytotoxic response as well as a clinical response. In this review, we discuss the potential of TCR-based cellular therapies in solid tumors. While various challenges exist with this therapy, multiple clinical trials are ongoing, in attempt to mitigate these limitations.
科研通智能强力驱动
Strongly Powered by AbleSci AI